Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(18):1352-1354; doi:10.1093/jnci/96.18.1352
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Research Unveils the 'Who' and 'Why' of Gefitinib

Brian Vastag

The first 10% of the full text of this article appears below.

When the U.S. Food and Drug Administration (FDA) approved the lung cancer drug gefitinib (Iressa) in May 2003, it was with the knowledge that the drug would be effective in only about 10% of patients. But researchers understood little about the characteristics of this subgroup that made them respond so well.

Sixteen months later, rapid research is providing answers to the "who" and the "why" of gefitinib.

"It's sort of a dream come true for [lung] cancer therapy," said Mark Kris, M.D., an oncologist at Memorial Sloan-Kettering Cancer Center in New York, who studies gefitinib. "It's all about finding the specific defect that causes the cancer or makes it persist, and then countering it."


Figure Removed (Available Only in the Full Text)
View larger version (152K):
[in this window]
[in a new window]
  		Dr. Mark Kris

 

Late last year, separate groups at Massachusetts General Hospital and Dana-Farber Cancer Institute, both in Boston, discovered why only a small fraction of patients benefit . . . [Full Text of this Article]

Answering "Why?"

Cousin Drugs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?